Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.

Jin L, Wang J, Jin H, Fei G, Zhang Y, Chen W, Zhao L, Zhao N, Sun X, Zeng M, Zhong C.

Eur J Neurol. 2012 Jul;19(7):969-76. doi: 10.1111/j.1468-1331.2011.03658.x. Epub 2012 Jan 30.

PMID:
22288465
2.

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C.

Brain. 2011 Jan;134(Pt 1):50-8. doi: 10.1093/brain/awq319. Epub 2010 Nov 24.

3.

Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.

Kim TH, Lee JH.

PLoS One. 2014 Nov 11;9(11):e112512. doi: 10.1371/journal.pone.0112512. eCollection 2014.

4.

Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease.

Bunzeck N, Singh-Curry V, Eckart C, Weiskopf N, Perry RJ, Bain PG, Düzel E, Husain M.

Parkinsonism Relat Disord. 2013 Dec;19(12):1136-42. doi: 10.1016/j.parkreldis.2013.08.011. Epub 2013 Aug 29.

5.

Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.

He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, Liu C, Chen K, Yan F.

Hum Brain Mapp. 2015 Nov;36(11):4407-20. doi: 10.1002/hbm.22928. Epub 2015 Aug 7.

PMID:
26249218
6.

Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.

Scherfler C, Esterhammer R, Nocker M, Mahlknecht P, Stockner H, Warwitz B, Spielberger S, Pinter B, Donnemiller E, Decristoforo C, Virgolini I, Schocke M, Poewe W, Seppi K.

Brain. 2013 Oct;136(Pt 10):3028-37. doi: 10.1093/brain/awt234. Epub 2013 Sep 6.

7.

Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.

Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, Huang X.

PLoS One. 2012;7(4):e35397. doi: 10.1371/journal.pone.0035397. Epub 2012 Apr 17.

8.

Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.

Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, Dai Y, Feng H.

Brain Res. 2010 May 12;1330:124-30. doi: 10.1016/j.brainres.2010.03.036. Epub 2010 Mar 18.

PMID:
20303339
9.

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.

Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD.

J Neurochem. 1989 Jun;52(6):1830-6.

PMID:
2723638
10.

T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.

Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE.

Neurol India. 2004 Sep;52(3):332-7.

11.

Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.

Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD.

Brain. 2000 Dec;123 Pt 12:2423-31. Erratum in: Brain 2001 Jun;124(Pt 6):1258.

12.

Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.

Wu SF, Zhu ZF, Kong Y, Zhang HP, Zhou GQ, Jiang QT, Meng XP.

Eur Rev Med Pharmacol Sci. 2014;18(18):2605-8.

13.

Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.

Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P.

Acad Radiol. 2014 Jan;21(1):64-71. doi: 10.1016/j.acra.2013.09.018.

PMID:
24331266
14.

Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.

Martínez-Hernández R, Montes S, Higuera-Calleja J, Yescas P, Boll MC, Diaz-Ruiz A, Rios C.

Neurochem Res. 2011 Nov;36(11):2111-5. doi: 10.1007/s11064-011-0535-x. Epub 2011 Jun 26.

PMID:
21706376
15.

Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O.

J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):737-41.

16.

Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.

Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA.

Neurology. 1995 Jun;45(6):1138-43. Erratum in: Neurology 1995 Jul;45(7):1420.

PMID:
7783878
17.

Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.

Wang C, Fan G, Xu K, Wang S.

Magn Reson Imaging. 2013 Sep;31(7):1068-73. doi: 10.1016/j.mri.2013.04.015. Epub 2013 Jun 6.

PMID:
23746648
18.

Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.

Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y.

J Neurochem. 1991 Feb;56(2):446-51.

PMID:
1988548
19.

Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study.

Guan X, Xuan M, Gu Q, Xu X, Huang P, Wang N, Shen Z, Xu J, Luo W, Zhang M.

J Magn Reson Imaging. 2016 Aug 22. doi: 10.1002/jmri.25434. [Epub ahead of print]

PMID:
27545971
20.

Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U.

Brain. 2010 Nov;133(11):3423-33. doi: 10.1093/brain/awq212. Epub 2010 Aug 23.

Items per page

Supplemental Content

Write to the Help Desk